Mouse Models of Human Myeloma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 6, 2007, Pages 1051-1069

  Mitsiades, Constantine S ^a   Anderson, Kenneth C ^a   Carrasco, Daniel R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE LESION; CANCER CELL CULTURE; DISEASE MODEL; GENETIC MODEL; HUMAN; IMMUNE DEFICIENCY; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCID MOUSE; XENOGRAFT;

ANIMALS; BONE TRANSPLANTATION; CHIMERA; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; MULTIPLE MYELOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 35748946662     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.08.003     Document Type: Review

References (114)

1. Mitsiades C.S., Mitsiades N., Munshi N.C., et al. Focus on multiple myeloma. Cancer Cell 6 5 (2004) 439-444
2. Urashima M., Chen B.P., Chen S., et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90 2 (1997) 754-765
3. Hjorth-Hansen H., Seifert M.F., Borset M., et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14 2 (1999) 256-263
4. Mitsiades C.S., Mitsiades N.S., Bronson R.T., et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63 20 (2003) 6689-6696
5. Radl J., De Glopper E.D., Schuit H.R., et al. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122 2 (1979) 609-613
6. Tong A.W., Huang Y.W., Zhang B.Q., et al. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Anticancer Res 13 3 (1993) 593-597
7. LeBlanc R., Catley L.P., Hideshima T., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62 17 (2002) 4996-5000
8. Chauhan D., Hideshima T., and Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 95 8 (2006) 961-965
9. Lentzsch S., Rogers M.S., LeBlanc R., et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 62 8 (2002) 2300-2305
10. Sydor J.R., Normant E., Pien C.S., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 103 46 (2006) 17408-17413
11. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 10 (2006) 4053-4062
12. Trudel S., Stewart A.K., Rom E., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107 10 (2006) 4039-4046
13. Trudel S., Ely S., Farooqi Y., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103 9 (2004) 3521-3528
14. Trudel S., Li Z.H., Wei E., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 7 (2005) 2941-2948
15. Mitsiades C.S., Treon S.P., Mitsiades N., et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98 3 (2001) 795-804
16. Trudel S., Stewart A.K., Li Z., et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13 2 Pt 1 (2007) 621-629
17. Podar K., Tonon G., Sattler M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 103 51 (2006) 19478-19483
18. Navas T.A., Nguyen A.N., Hideshima T., et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20 6 (2006) 1017-1027
19. Lin B., Catley L., LeBlanc R., et al. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 105 1 (2005) 350-357
20. Yan H., Frost P., Shi Y., et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66 4 (2006) 2305-2313
21. Suzuki H., Yasukawa K., Saito T., et al. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22 8 (1992) 1989-1993
22. Ozaki S., Kosaka M., Harada M., et al. Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. Cancer 82 11 (1998) 2184-2190
23. Hideshima T., Bergsagel P.L., Kuehl W.M., et al. Advances in biology of multiple myeloma: clinical applications. Blood 104 3 (2004) 607-618
24. Namikawa R., Kaneshima H., Lieberman M., et al. Infection of the SCID-hu mouse by HIV-1. Science 242 4886 (1988) 1684-1686
25. McCune J.M., Namikawa R., Kaneshima H., et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241 4873 (1988) 1632-1639
26. Yaccoby S., Barlogie B., and Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92 8 (1998) 2908-2913
27. Epstein J., and Yaccoby S. The SCID-hu myeloma model. Methods Mol Med 113 (2005) 183-190
28. Yaccoby S., and Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94 10 (1999) 3576-3582
29. Yaccoby S., Johnson C.L., Mahaffey S.C., et al. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 100 12 (2002) 4162-4168
30. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98 20 (2001) 11581-11586
31. Yaccoby S., Pearse R.N., Johnson C.L., et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116 2 (2002) 278-290
32. Sordillo E.M., and Pearse R.N. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 97 3 Suppl (2003) 802-812
33. Hideshima T., Neri P., Tassone P., et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 12 19 (2006) 5887-5894
34. Zhu K., Gerbino E., Beaupre D.M., et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105 12 (2005) 4759-4766
35. Tassone P., Goldmacher V.S., Neri P., et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104 12 (2004) 3688-3696
36. Araki K., Sangai T., Miyamoto S., et al. Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. Int J Cancer 118 10 (2006) 2602-2608
37. Tassone P., Neri P., Burger R., et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 11 11 (2005) 4251-4258
38. Tassone P., Gozzini A., Goldmacher V., et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 64 13 (2004) 4629-4636
39. Yata K., and Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18 11 (2004) 1891-1897
40. Pilarski L.M., Hipperson G., Seeberger K., et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95 3 (2000) 1056-1065
41. Pilarski L.M., Seeberger K., Coupland R.W., et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 30 3 (2002) 221-228
42. Tsunenari T., Koishihara Y., Nakamura A., et al. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 90 6 (1997) 2437-2444
43. Miyakawa Y., Ohnishi Y., Tomisawa M., et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 313 2 (2004) 258-262
44. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 3 (2004) 221-230
45. Dewan M.Z., Watanabe M., Terashima K., et al. Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci 95 7 (2004) 564-568
46. Wu K.D., Cho Y.S., Katz J., et al. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A 102 30 (2005) 10640-10645
47. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107 3 (2006) 1092-1100
48. Xin X., Abrams T.J., Hollenbach P.W., et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12 16 (2006) 4908-4915
49. Carlo-Stella C., Guidetti A., Di Nicola M., et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Exp Hematol 34 6 (2006) 721-727
50. Baughn L.B., Di Liberto M., Wu K., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 66 15 (2006) 7661-7667
51. Wu K.D., Zhou L., Burtrum D., et al. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56 3 (2007) 343-357
52. Huang Y.W., Richardson J.A., Tong A.W., et al. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53 6 (1993) 1392-1396
53. Alsina M., Boyce B.F., Mundy G.R., et al. An in vivo model of human multiple myeloma bone disease. Stem Cells 13 Suppl 2 (1995) 48-50
54. Alsina M., Boyce B., Devlin R.D., et al. Development of an in vivo model of human multiple myeloma bone disease. Blood 87 4 (1996) 1495-1501
55. Bellamy W.T., Mendibles P., Bontje P., et al. Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype. Cancer Chemother Pharmacol 37 4 (1996) 305-316
56. Drexler H.G., Matsuo Y., and MacLeod R.A. Persistent use of false myeloma cell lines. Hum Cell 16 3 (2003) 101-105
57. Pilarski L.M., and Belch A.R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res 8 10 (2002) 3198-3204
58. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2 3 (2002) 175-187
59. Tassone P., Neri P., Carrasco D.R., et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106 2 (2005) 713-716
60. Alici E., Konstantinidis K.V., Aints A., et al. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 32 11 (2004) 1064-1072
61. Heath D.J., Vanderkerken K., Cheng X., et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 67 1 (2007) 202-208
62. Potter M. Neoplastic development in plasma cells. Immunol Rev 194 (2003) 177-195
63. Libouban H., Moreau M.F., Basle M.F., et al. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone 33 3 (2003) 283-292
64. Croucher P.I., Shipman C.M., Van Camp B., et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 97 3 Suppl (2003) 818-824
65. Asosingh K., Vankerkhove V., Van Riet I., et al. Selective in vivo growth of lymphocyte function- associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion. Exp Hematol 31 1 (2003) 48-55
66. Asosingh K. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma. Verh K Acad Geneeskd Belg 65 2 (2003) 127-134
67. Vanderkerken K., Vande Broek I., Eizirik D.L., et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 19 1 (2002) 87-90
68. Van Valckenborgh E., De Raeve H., Devy L., et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 86 5 (2002) 796-802
69. Van Valckenborgh E., Bakkus M., Munaut C., et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 101 6 (2002) 512-518
70. Menu E., Braet F., Timmers M., et al. The F-actin content of multiple myeloma cells as a measure of their migration. Ann N Y Acad Sci 973 (2002) 124-136
71. Asosingh K., Menu E., Van Valckenborgh E., et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis 19 7 (2002) 583-591
72. Mittelman M., Neumann D., Peled A., et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 98 9 (2001) 5181-5186
73. Henry J.M., Morley A.A., and Sykes P.J. Purging of myeloma cells using all-trans retinoic acid in a mouse model. Exp Hematol 29 3 (2001) 315-321
74. Bakkus M.H., Asosingh K., Vanderkerken K., et al. Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia 15 7 (2001) 1127-1132
75. Asosingh K., Gunthert U., De Raeve H., et al. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 61 7 (2001) 2862-2865
76. Asosingh K., De Raeve H., Croucher P., et al. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol 29 1 (2001) 77-84
77. Vanderkerken K., Van Camp B., De Greef C., et al. Homing of the myeloma cell clone. Acta Oncol 39 7 (2000) 771-776
78. Vanderkerken K., De Greef C., Asosingh K., et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer 82 4 (2000) 953-959
79. Oyajobi B.O., Deng J.H., Dallas S.L., et al. Absence of herpesvirus DNA sequences in the 5T murine model of human multiple myeloma. Br J Haematol 109 2 (2000) 413-419
80. Asosingh K., Radl J., Van Riet I., et al. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 1 5 (2000) 351-356
81. Vanderkerken K., Asosingh K., Braet F., et al. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 93 1 (1999) 235-241
82. Manning L.S., and Radin N.S. Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells. Br J Cancer 81 6 (1999) 952-958
83. Zhu D., van Arkel C., King C.A., et al. Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease. Immunology 93 2 (1998) 162-170
84. Vanderkerken K., De Raeve H., Goes E., et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 76 4 (1997) 451-460
85. Vanderkerken K., Goes E., De Raeve H., et al. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br J Cancer 73 12 (1996) 1463-1465
86. van den Akker T.W., Radl J., Franken-Postma E., et al. Cytogenetic findings in mouse multiple myeloma and Waldenstrom's macroglobulinemia. Cancer Genet Cytogenet 86 2 (1996) 156-161
87. Bradley T.R., Kriegler A.B., Verschoor S.M., et al. Interaction between a murine myeloma cell line and bone marrow stromal cells. Exp Hematol 24 2 (1996) 307-309
88. Manning L.S., Chamberlain N.L., Leahy M.F., et al. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model. Immunol Cell Biol 73 4 (1995) 326-332
89. Turner J.H., Claringbold P.G., Manning L.S., et al. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation. J Natl Cancer Inst 85 18 (1993) 1508-1513
90. Manning L.S., Berger J.D., O'Donoghue H.L., et al. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 66 6 (1992) 1088-1093
91. Croese J.W., Vissinga C.S., Boersma W.J., et al. Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype. Neoplasma 38 5 (1991) 457-466
92. Croese J.W., Van den Enden-Vieveen M.H., and Radl J. Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma 38 5 (1991) 467-474
93. Radl J., Punt Y.A., van den Enden-Vieveen M.H., et al. The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations. Br J Cancer 61 2 (1990) 276-278
94. Croese J.W., Vas Nunes C.M., Radl J., et al. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer 56 5 (1987) 555-560
95. Radl J., Croese J.W., Zurcher C., et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 55 5 (1985) 1030-1040
96. Radl J., Hollander C.F., van den Berg P., et al. Idiopathic paraproteinaemia. I. Studies in an animal model-the ageing C57BL/KaLwRij mouse. Clin Exp Immunol 33 3 (1978) 395-402
97. Menu E., De Leenheer E., De Raeve H., et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 23 5-6 (2006) 291-300
98. Menu E., Asosingh K., Indraccolo S., et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91 5 (2006) 605-612
99. Asosingh K., De Raeve H., de Ridder M., et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 90 6 (2005) 810-817
100. Croucher P.I., De Hendrik R., Perry M.J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18 3 (2003) 482-492
101. Menu E., Jernberg-Wiklund H., Stromberg T., et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107 2 (2006) 655-660
102. Edwards C.M., Mueller G., Roelofs A.J., et al. Apominetrade mark, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer 120 8 (2007) 1657-1663
103. Libouban H., Moreau M.F., Basle M.F., et al. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse. Biochem Biophys Res Commun 316 3 (2004) 859-866
104. Campbell R.A., Manyak S.J., Yang H.H., et al. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol 28 6 (2006) 1409-1417
105. Iwakoshi N.N., Lee A.H., and Glimcher L.H. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev 194 (2003) 29-38
106. Radl J. Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris) 47 2 (1999) 109-114
107. Potter M. Experimental plasmacytomagenesis in mice. Hematol Oncol Clin North Am 11 2 (1997) 323-347
108. Zhang S.L., DuBois W., Ramsay E.S., et al. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 21 1 (2001) 310-318
109. Kovalchuk A.L., Kim J.S., Park S.S., et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 99 3 (2002) 1509-1514
110. Chiarle R., Gong J.Z., Guasparri I., et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101 5 (2003) 1919-1927
111. Cheung W.C., Kim J.S., Linden M., et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 113 12 (2004) 1763-1773
112. Kim J.S., Han S.S., Park S.S., et al. Plasma cell tumour progression in iMycEmu gene-insertion mice. J Pathol 209 1 (2006) 44-55
113. Sebag M., Stewart K., Palmer S., et al. A novel transgenic mouse model of multiple myeloma reliably predicts drug response. Blood 108 11 (2006) 75a
114. Carrasco D.R., Sukhdeo K., Protopopova M., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11 4 (2007) 349-360